1-8 of 8
Laszlo Rejto
Close
Sort by
Journal Articles

Molecular Landscape of Chronic Lymphocytic Leukemia Using Targeted Gene Panel Sequencing

Agnes Mosolygo-Lukacs, Maria Balogh, Lajos Gergely, Laszlo Rejto, Robert Szasz, Aniko Ujfalusi
Journal: Blood
Blood (2022) 140 (Supplement 1): 4993–4994.
https://doi.org/10.1182/blood-2022-157284
Published: 2022
Journal Articles

Efficacy and Safety of Venetoclax Combinations in t(11;14) Multiple Myeloma: Real World Data Collected from 7 Hungarian Centers

Virág Réka Szita, MD, Gábor Mikala, MD PhD, János Fábián, MD, Péter Rajnics, MD PhD, László Rejtő, MD PhD, Tamás Szendrei, MD, Hussain Alizadeh, MD PhD DSc, Laszlo Varoczy, MD PhD, Árpád Illés, MD PhD, Tamas Masszi, MD PhD, Gergely Varga, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-139870
Published: 2020
Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2945.
https://doi.org/10.1182/blood-2019-123836
Published: 2019
Journal Articles

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Adrian C. Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans De Haard, Nicolas Leupin, David J. Kuter
Journal: Blood
Blood (2019) 134 (Supplement_1): 895.
https://doi.org/10.1182/blood-2019-128022
Published: 2019
Journal Articles

Retrospective Comparison Of Autologous Transplantation Results Of Decreased MNC Viability Graft Cases (n=52) To Good Viability Graft Cases (n=306), a Single Centre Experience

Mariann Szarvas, Gabriella Kovács, Zita Korondán, Peter Batar, MD, PhD, Attila Kiss, MD, PhD, László Rejtö, MD, PhD, Gyula Reményi, MD, Róbert Szász, MD, László Váróczy, MD, PhD, Árpád Illés, MD, PhD, DSc, Miklós Udvardy, MD, PhD, DSc
Journal: Blood
Blood (2013) 122 (21): 2164.
https://doi.org/10.1182/blood.V122.21.2164.2164
Published: 2013
Journal Articles

The Effect of Bortezomib Containing Induction On the Long Term Outcome of autologous Haemopoietic Stem Cell Transplantation in Multiple Myeloma Patients Outside Clinical Trials - a Single Center Experience

Miklos Udvardy, MD, PhD, Remenyi Gyula, Attila Kiss, Prof. Dr., Peter Batar, Dr, Arpad Illes, MD, PhD, Dsc, Laszló Varoczy, MD PhD, Gaspar Radvanyi, MD, Robert Szasz, PhD, MD, Laszlo Rejto, PhD, MD
Journal: Blood
Blood (2012) 120 (21): 5050.
https://doi.org/10.1182/blood.V120.21.5050.5050
Published: 2012
Journal Articles

A New Approach to Predict the Chance of Infectious Complications Following Autologous Hematopoietic Stem Cell Transplantation: Mannose-Binding Lectin ELISA

Zita Radnay, MD, Miklos Udvardy, PhD, MD, Attila Kiss, PhD, MD, Maria Papp, PhD, MD, Laszlo Rejto, PhD, MD, Jolan Harsfalvi, PhD, Tamas Masszi, MD, PhD, Robert Szasz, PhD, MD, Peter Batar, MD, PhD, Gyula Remenyi, MD, Bela Telek, PhD, MD
Journal: Blood
Blood (2011) 118 (21): 4492.
https://doi.org/10.1182/blood.V118.21.4492.4492
Published: 2011
Journal Articles

Bortezomib+Chemotherapy Based Salvage Combinations in Refractory AML, Preliminary Results

Miklos Udvardy, Attila Kiss, Bela Telek, Robert Szasz, Peter Batar, Gyula Remenyi, Andrew Cakana, Laszlo Rejto
Journal: Blood
Blood (2008) 112 (11): 4000.
https://doi.org/10.1182/blood.V112.11.4000.4000
Published: 2008